New drug shows promise for Long-Term control of ulcerative colitis
NCT ID NCT04277546
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the long-term safety of brazikumab, a drug given as a shot every 4 weeks, for people with moderate to severe ulcerative colitis. Participants had already taken part in an earlier study of brazikumab. The goal is to see if the drug remains safe over a longer period and to gather information for possible future approval.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brazikumab
What this could lead to
If successful, this could provide a long-term treatment option for people with moderate to severe ulcerative colitis.
What could go wrong
This is an early-phase, small study focused on safety, not proof of cure. The drug may not work for everyone and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Chula Vista, California, 91911, United States
-
Research Site
Lancaster, California, 93534, United States
-
Research Site
Colorado Springs, Colorado, 80907, United States
-
Research Site
Lakeland, Florida, 33813, United States
-
Research Site
Miami, Florida, 33165, United States
-
Research Site
Miami Lakes, Florida, 33016, United States
-
Research Site
Evansville, Indiana, 47715, United States
-
Research Site
Beachwood, Ohio, 44122, United States
-
Research Site
Oklahoma City, Oklahoma, 73112, United States
-
Research Site
Humble, Texas, 77346, United States
-
Research Site
České Budějovice, 370 01, Czechia
-
Research Site
Ostrava, 702 00, Czechia
-
Research Site
Hamburg, 20251, Germany
-
Research Site
Kiel, 24105, Germany
-
Research Site
Ulm, 89081, Germany
-
Research Site
Haifa, 3109601, Israel
-
Research Site
Jerusalem, 9103102, Israel
-
Research Site
Milan, 20132, Italy
-
Research Site
Rho, 20017, Italy
-
Research Site
Roma, 00168, Italy
-
Research Site
Kasama-shi, 309-1793, Japan
-
Research Site
Kashiwa-shi, 277-0871, Japan
-
Research Site
Minatoku, 108-8642, Japan
-
Research Site
Krakow, 31-513, Poland
-
Research Site
Rzeszów, 35-302, Poland
-
Research Site
Sopot, 81-756, Poland
-
Research Site
Torun, 87-100, Poland
-
Research Site
Warsaw, 00-189, Poland
-
Research Site
Warsaw, 03-580, Poland
-
Research Site
San Juan, 00927, Puerto Rico
-
Research Site
Cape Town, 7500, South Africa
-
Research Site
Cape Town, 7708, South Africa
-
Research Site
Plumstead, 7800, South Africa
-
Research Site
Wŏnju, 26426, South Korea
-
Research Site
Taichung, 40447, Taiwan
-
Research Site
Taipei, 10002, Taiwan